Stryker Co. (NYSE:SYK) Shares Purchased by Sumitomo Mitsui Trust Group Inc.

Sumitomo Mitsui Trust Group Inc. lifted its holdings in Stryker Co. (NYSE:SYK - Free Report) by 2.9% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,143,573 shares of the medical technology company's stock after buying an additional 32,491 shares during the quarter. Sumitomo Mitsui Trust Group Inc. owned approximately 0.30% of Stryker worth $413,127,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Vanguard Group Inc. lifted its stake in Stryker by 1.0% during the 1st quarter. Vanguard Group Inc. now owns 31,459,393 shares of the medical technology company's stock valued at $11,258,373,000 after acquiring an additional 309,592 shares during the period. JPMorgan Chase & Co. increased its holdings in Stryker by 10.4% in the 1st quarter. JPMorgan Chase & Co. now owns 8,651,403 shares of the medical technology company's stock worth $3,096,078,000 after acquiring an additional 813,311 shares in the last quarter. Clearbridge Investments LLC increased its holdings in Stryker by 2.9% in the 2nd quarter. Clearbridge Investments LLC now owns 2,323,452 shares of the medical technology company's stock worth $790,554,000 after acquiring an additional 66,482 shares in the last quarter. TD Asset Management Inc grew its holdings in Stryker by 2.9% during the 1st quarter. TD Asset Management Inc now owns 1,601,380 shares of the medical technology company's stock valued at $573,086,000 after buying an additional 44,765 shares in the last quarter. Finally, The Manufacturers Life Insurance Company grew its holdings in Stryker by 4.0% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 1,209,769 shares of the medical technology company's stock valued at $411,624,000 after buying an additional 46,375 shares in the last quarter. 77.09% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Stryker

In other Stryker news, VP M Kathryn Fink sold 2,121 shares of the company's stock in a transaction on Friday, September 13th. The shares were sold at an average price of $370.00, for a total transaction of $784,770.00. Following the completion of the transaction, the vice president now directly owns 10,042 shares in the company, valued at approximately $3,715,540. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In related news, VP M Kathryn Fink sold 2,121 shares of the company's stock in a transaction dated Friday, September 13th. The shares were sold at an average price of $370.00, for a total value of $784,770.00. Following the completion of the sale, the vice president now owns 10,042 shares of the company's stock, valued at approximately $3,715,540. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO Kevin Lobo sold 57,313 shares of the company's stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $368.70, for a total transaction of $21,131,303.10. Following the completion of the sale, the chief executive officer now directly owns 100,027 shares of the company's stock, valued at $36,879,954.90. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 67,381 shares of company stock worth $24,825,275 in the last three months. Company insiders own 5.90% of the company's stock.

Stryker Stock Up 2.4 %

Shares of SYK stock traded up $9.02 during trading hours on Tuesday, reaching $387.88. 787,722 shares of the company's stock were exchanged, compared to its average volume of 1,250,769. Stryker Co. has a 1 year low of $276.60 and a 1 year high of $388.00. The stock has a market cap of $147.87 billion, a PE ratio of 40.61, a PEG ratio of 2.83 and a beta of 0.91. The company has a current ratio of 1.91, a quick ratio of 1.22 and a debt-to-equity ratio of 0.66. The stock's fifty day moving average price is $361.83 and its two-hundred day moving average price is $346.06.

Stryker (NYSE:SYK - Get Free Report) last released its earnings results on Tuesday, October 29th. The medical technology company reported $2.87 EPS for the quarter, topping analysts' consensus estimates of $2.77 by $0.10. Stryker had a return on equity of 23.07% and a net margin of 16.34%. The firm had revenue of $5.49 billion during the quarter, compared to the consensus estimate of $5.37 billion. During the same quarter in the previous year, the company posted $2.46 earnings per share. The company's revenue was up 11.9% compared to the same quarter last year. Research analysts predict that Stryker Co. will post 12.06 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on SYK shares. BTIG Research raised their target price on shares of Stryker from $383.00 to $394.00 and gave the company a "buy" rating in a report on Wednesday, October 30th. Barclays raised their price target on Stryker from $402.00 to $418.00 and gave the stock an "overweight" rating in a research report on Thursday, October 31st. Truist Financial raised their price target on Stryker from $370.00 to $380.00 and gave the stock a "hold" rating in a research report on Wednesday, October 30th. Morgan Stanley raised their price target on Stryker from $345.00 to $350.00 and gave the stock an "equal weight" rating in a research report on Monday, July 15th. Finally, StockNews.com downgraded Stryker from a "buy" rating to a "hold" rating in a research report on Wednesday, November 6th. Five equities research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $393.65.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.